Clinical value of serum SIRT1 combined with uterine hemodynamics in predicting disease severity and fetal growth restriction in preeclampsia
Abstract
Objective
To investigate the effect and correlation of serum SIRT1 combined with uterine hemodynamic parameters on disease severity and fetal uterine growth restriction in the progression of preeclampsia, and to evaluate its clinical value as potential markers.
Methods
A total of 100 patients with preeclampsia who were hospitalized in Qufu Normal University Hospital from June 2017 to June 2021 were selected as the research objects. According to the severity, they were divided into Mild group (62 cases) and Severe group (38 cases), and according to whether the fetal growth restriction was combined or not, they were divided into the Combined fetal growth restriction group (56 cases) and the Uncomplicated fetal growth restriction group (44 cases). Serum SIRT1 expression and uterine artery hemodynamic parameters were detected, and spearman analysis was used to evaluate the association of serum SIRT1 expression and uterine artery hemodynamic parameters (peak-to-trough ratio of arterial blood velocity, pulsatility index, resistance index) with disease severity (systolic blood pressure, diastolic blood pressure, and random urinary protein levels) and fetal growth restriction (femoral length, biparietal diameter, head circumference and neonatal weight); unsupervised PCA analysis, supervised PLS-DA analysis, Cluster heat map analysis, ROC curve and AUC analysis were used to evaluate the diagnostic value of serum SIRT1 expression combined with uterine artery hemodynamic parameters in the severity of disease and fetal growth restriction in patients with preeclampsia.
Results
Serum SIRT1 expression was decreased in patients with severe preeclampsia (p < 0.0001), arterial blood flow velocity peak-to-trough ratio, pulsatility index and resistance index were increased (p < 0.001; p < 0.0001), and serum SIRT1 expression and uterine artery hemodynamic parameters were closely related to disease severity (p < 0.001; p < 0.0001). In addition, the expression of serum SIRT1 in patients with preeclampsia combined with fetal growth restriction was decreased (p < 0.0001), the peak-to-trough ratio of arterial blood flow velocity, pulsatility index and resistance index were increased (p < 0.0001), and serum SIRT1 expression and uterine artery hemodynamics were closely related to fetal growth restriction (p < 0.0001). Unsupervised PCA analysis and supervised PLS-DA analysis showed that patients with different severity of disease and patients with or without fetal growth restriction were similar within groups, and there were significant differences between groups; cluster heat map analysis showed that mild and severe groups were stratified clustering, the combined fetal growth restriction group and the uncombined group were hierarchically clustered; ROC curve and AUC analysis showed that serum SIRT1 expression combined with uterine artery hemodynamic parameters had a significant effect on the severity of preeclampsia and whether combined with fetal growth restriction. high diagnostic value.
Conclusion
Serum SIRT1 combined with uterine hemodynamic parameters in preeclampsia is closely related to disease severity and fetal growth restriction, and is expected to become potential biomarkers for early clinical intervention in patients.
References
[] Raia-Barjat T, Edebiri O, Ni Ainle F. Preeclampsia and Venous Thromboembolism: Pathophysiology and Potential Therapy. Front Cardiovasc Med. 2022 Mar 7;9:856923. doi: 10.3389/fcvm.2022.856923.
[] Zheng D, Khan M, Zhang G, Song K, Wang L, Qiao C, Kang F. A bibliometric analysis of the research on preeclampsia in the first two decades of the twenty-first century. J Hypertens. 2022 Mar 11. doi: 10.1097/HJH.0000000000003114.
[] Jung E, Romero R, Yeo L, Gomez-Lopez N, Chaemsaithong P, Jaovisidha A, Gotsch F, Erez O. The etiology of preeclampsia. Am J Obstet Gynecol. 2022 Feb;226(2S):S844-S866. doi: 10.1016/j.ajog.2021.11.1356.
[] Bright MA, Parrott M, Martin S, Thompson L, Roussos-Ross D, Montoya-Williams D. Streamlining Universal Prenatal Screening for Risk for Adverse Birth Outcomes. Matern Child Health J. 2022 Mar 21. doi: 10.1007/s10995-022-03420-7.
[] Kasuya M, Akiba N, Iriyama T, Sayama S, Kubota K, Toshimitsu M, Seyama T, Sone K, Kumasawa K, Nagamatsu T, Fujii T, Osuga Y. The impact of fetal growth restriction in diagnosing preeclampsia on the severity of maternal features. J Obstet Gynaecol Res. 2022 Mar 3. doi: 10.1111/jog.15152.
[] Paules C, Dantas AP, Miranda J, Crovetto F, Eixarch E, Rodriguez-Sureda V, Dominguez C, Casu G, Rovira C, Nadal A, Crispi F, Gratacós E. Premature placental aging in term small-for-gestational-age and growth-restricted fetuses. Ultrasound Obstet Gynecol. 2019 May;53(5):615-622. doi: 10.1002/uog.20103.
[] Amodeo S, Cavoretto PI, Seidenari A, Paci G, Germano C, Monari F, Donno V, Giambanco L, Avagliano L, Di Martino D, Fusé F, Masturzo B, Chiantera V, Facchinetti F, Ferrazzi E, Candiani M, Bulfamante G, Farina A. Second trimester uterine arteries pulsatility index is a function of placental pathology and provides insights on stillbirth aetiology: A multicenter matched case-control study. Placenta. 2022 Feb 26;121:7-13. doi: 10.1016/j.placenta.2022.02.021.
[] Nowakowska BA, Pankiewicz K, Nowacka U, Niemiec M, Kozłowski S, Issat T. Genetic Background of Fetal Growth Restriction. Int J Mol Sci. 2021 Dec 21;23(1):36. doi: 10.3390/ijms23010036.
[] Singh CK, Chhabra G, Ndiaye MA, Garcia-Peterson LM, Mack NJ, Ahmad N. The Role of Sirtuins in Antioxidant and Redox Signaling. Antioxid Redox Signal. 2018 Mar 10;28(8):643-661. doi: 10.1089/ars.2017.7290.
[] Yu H, Zhang Y, Liu M, Liao L, Wei X, Zhou R. SIRT3 deficiency affects the migration, invasion, tube formation and necroptosis of trophoblast and is implicated in the pathogenesis of preeclampsia. Placenta. 2022 Mar 24;120:1-9. doi: 10.1016/j.placenta.2022.01.014.
[] Wang M, Lin H. Understanding the Function of Mammalian Sirtuins and Protein Lysine Acylation. Annu Rev Biochem. 2021 Jun 20;90:245-285. doi: 10.1146/annurev-biochem-082520-125411.
[] Sakowicz A. The Targeting of Nuclear Factor Kappa B by Drugs Adopted for the Prevention and Treatment of Preeclampsia. Int J Mol Sci. 2022 Mar 7;23(5):2881. doi: 10.3390/ijms23052881.
[] Colloca A, Balestrieri A, Anastasio C, Balestrieri ML, D'Onofrio N. Mitochondrial Sirtuins in Chronic Degenerative Diseases: New Metabolic Targets in Colorectal Cancer. Int J Mol Sci. 2022 Mar 16;23(6):3212. doi: 10.3390/ijms23063212.
[] Nogueiras R, Habegger KM, Chaudhary N, Finan B, Banks AS, Dietrich MO, Horvath TL, Sinclair DA, Pfluger PT, Tschöp MH. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012 Jul;92(3):1479-514. doi: 10.1152/physrev.00022.2011.
[] Huang Y, Zheng XD, Li H. Protective role of SIRT1-mediated Sonic Hedgehog signaling pathway in the preeclampsia rat models. J Assist Reprod Genet. 2021 Jul;38(7):1843-1851. doi: 10.1007/s10815-021-02158-5.
[] Viana-Mattioli S, Nunes P, Cavalli R, Sandrim V. Analysis of SIRT1 Expression in Plasma and in an In Vitro Model of Preeclampsia. Oxid Med Cell Longev. 2020 Apr 28;2020:4561083. doi: 10.1155/2020/4561083.
[] Rodriguez-Fernandez JJ, Martinez-Garza LE, Sepulveda-Gonzalez G, Hernandez-Castro F, Gaston-Locsin T. Serum biomarkers and Doppler pulsatile index increases likelihood ratio for prediction of preeclampsia in the second trimester of pregnancy. J Obstet Gynaecol. 2022 Feb 21:1-6. doi: 10.1080/01443615.2022.2035331.
[] Tian Y, Yang X. A Review of Roles of Uterine Artery Doppler in Pregnancy Complications. Front Med (Lausanne). 2022 Mar 3;9:813343. doi: 10.3389/fmed.2022.813343.
[] Trottmann F, Mollet AE, Amylidi-Mohr S, Surbek D, Raio L, Mosimann B. Integrating Combined First Trimester Screening for Preeclampsia into Routine Ultrasound Examination. Geburtshilfe Frauenheilkd. 2022 Mar 3;82(3):333-340. doi: 10.1055/a-1534-2599.
[] Natenzon A, McFadden P, DaSilva-Arnold SC, Zamudio S, Illsley NP. Diminished trophoblast differentiation in early onset preeclampsia. Placenta. 2022 Mar 24;120:25-31. doi: 10.1016/j.placenta.2022.02.004.
[] Suresh S, Amegashie C, Patel E, Nieman KM, Rana S. Racial Disparities in Diagnosis, Management, and Outcomes in Preeclampsia. Curr Hypertens Rep. 2022 Apr;24(4):87-93. doi: 10.1007/s11906-022-01172-x.
[] Mkhize PZ, Phoswa WN, Khaliq OP, Dorsamy V, Moodley J. Aspirin in the prevention of preeclampsia: A protocol for systematic review and meta analysis. Medicine (Baltimore). 2021 Dec 3;100(48):e27916. doi: 10.1097/MD.0000000000027916.
[] Takahashi M, Makino S, Oguma K, Imai H, Takamizu A, Koizumi A, Yoshida K. Fetal growth restriction as the initial finding of preeclampsia is a clinical predictor of maternal and neonatal prognoses: a single-center retrospective study. BMC Pregnancy Childbirth. 2021 Oct 6;21(1):678. doi: 10.1186/s12884-021-04152-2.
[] Yao M, Xiao Y, Yang Z, Ge W, Liang F, Teng H, Gu Y, Yin J. Identification of Biomarkers for Preeclampsia Based on Metabolomics. Clin Epidemiol. 2022 Mar 19;14:337-360. doi: 10.2147/CLEP.S353019.
[] Hendershot JM, Abbasi M, Fortier L, Benn M, Giacobone C, Del Mastro R, Bahrami-Samani E, Mazloom AR, Oberoi P. Analytical validation of a novel panel of biomarkers for a test for preeclampsia. J Pharm Biomed Anal. 2022 Mar 18;214:114729. doi: 10.1016/j.jpba.2022.114729.
[] Lee KM, Seo HW, Kwon MS, Han AR, Lee SK. SIRT1 negatively regulates invasive and angiogenic activities of the extravillous trophoblast. Am J Reprod Immunol. 2019 Oct;82(4):e13167. doi: 10.1111/aji.13167.
[] Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014 Mar;25(3):138-45. doi: 10.1016/j.tem.2013.12.001.
[] Pham J, Arul Nambi Rajan K, Li P, Parast MM. The role of Sirtuin1-PPARγ axis in placental development and function. J Mol Endocrinol. 2018 May;60(4):R201-R212. doi: 10.1530/JME-17-0315.
[] Broady AJ, Loichinger MH, Ahn HJ, Davy PM, Allsopp RC, Bryant-Greenwood GD. Protective proteins and telomere length in placentas from patients with pre-eclampsia in the last trimester of gestation. Placenta. 2017 Feb;50:44-52. doi: 10.1016/j.placenta.2016.12.018.
[] Furuya N, Hasegawa J, Doi M, Koike J, Suzuki N. Accuracy of Prenatal Ultrasound in Evaluating Placental Pathology Using Superb Microvascular Imaging: A Prospective Observation Study. Ultrasound Med Biol. 2022 Jan;48(1):27-34. doi: 10.1016/j.ultrasmedbio.2021.09.002.
[] Bertholdt C, Hossu G, Banasiak C, Beaumont M, Morel O. First trimester screening for pre-eclampsia and intrauterine growth restriction using three-dimensional Doppler angiography (SPIRIT): protocol for a multicentre prospective study in nulliparous pregnant women. BMJ Open. 2020 Oct 19;10(10):e037751. doi: 10.1136/bmjopen-2020-037751.
Copyright (c) 2023 JianYing Kong, TongJun Ge
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.